Quantification of the irreversible fibroblast growth factor receptor inhibitor futibatinib by UPLC-MS/MS: Application to the metabolic stability assay in human liver microsomes for the estimation of its in vitro hepatic intrinsic clearance

被引:6
|
作者
Tang, Lloyd Wei Tat [1 ]
Chan, Eric Chun Yong [1 ]
机构
[1] Natl Univ Singapore, Dept Pharm, Fac Sci, Singapore, Singapore
关键词
Futibatinib; UPLC-MS/MS; Human liver microsomes; Metabolic stability; Intrinsic clearance;
D O I
10.1016/j.jpba.2022.114731
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Futibatinib (FUT) is a potent irreversible inhibitor of fibroblast growth factor receptor 1-4 currently under clinical investigation for the treatment of cholangiocarcinoma. However, there remains a paucity of information pertaining to its hepatic metabolism. In this study, our overarching aims were to systematically develop and validate a novel ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) analytical method to quantify FUT for the subsequent application to the metabolic stability assay. Chromatographic separation was achieved on a C18 column and a gradient elution system comprising 0.1% formic acid in water (A) and acetonitrile (B). Positive electrospray ionization in conjunction with multiple reaction monitoring (MRM) mode was harnessed for the selective and sensitive quantification of FUT (m/z 419.2-* 296.0) and erdafitinib (m/z 447.0-* 362.0; internal standard). The retention time was 1.49 min for FUT and 1.29 min for erdafitinib. The calibration curve was linear from 0.003 to 3 mu M (r2 > 0.99) and the lower limit of quantification was 0.003 mu M. The intra-day and inter-day precision (% RSD) and accuracy (% bias) were all < 11.4% and < 11.3% respectively. Quality control samples were determined to be stable under several conditions routinely employed in sample preparation and UPLC-MS/MS analyses. Moreover, the liver microsomal matrix did not adversely affect the quantification of FUT. Following which, the in vitro microsomal intrinsic clearance (CLint) of FUT was calculated from our metabolic stability assay to be 29.3 mu L/min/mg, thereby suggesting that it was a medium clearance drug. Finally, extrapolating the CLint with human scaling factors yielded an estimated in vitro hepatic intrinsic clearance value of 2075 mL/min. Our study reports the first UPLC-MS/MS method and offers a specific, sensitive and rapid means of determining FUT human liver microsomal stability.
引用
收藏
页数:7
相关论文
共 14 条
  • [1] Validated and green UPLC-MS/MS method for belumosudil quantification in human liver microsomes: Application to in vitro metabolic stability assessment
    Attwa, Mohamed W.
    Abdelhameed, Ali S.
    Kadi, Adnan A.
    ACTA CHROMATOGRAPHICA, 2025,
  • [2] An UPLC-ESI-MS/MS Bioanalytical Methodology for the Quantification of Gilteritinib in Human Liver Microsomes: Application to In Vitro and In Silico Metabolic Stability Estimation
    Attwa, Mohamed W.
    AlRabiah, Haitham
    Alsibaee, Aishah M.
    Abdelhameed, Ali S.
    Kadi, Adnan A.
    SEPARATIONS, 2023, 10 (05)
  • [3] Development of a Fast and Sensitive UPLC-MS/MS Analytical Methodology for Fenebrutinib Estimation in Human Liver Microsomes: In Vitro and In Silico Metabolic Stability Evaluation
    Attwa, Mohamed W.
    Alsibaee, Aishah M.
    Aljohar, Haya I.
    Abdelhameed, Ali S.
    Kadi, Adnan A.
    SEPARATIONS, 2023, 10 (05)
  • [4] An ultra-fast validated green UPLC-MS/MS method for the quantification of osimertinib in human liver microsomes: Screening for ADME parameters and in vitro metabolic stability
    Attwa, Mohamed W.
    Abdelhameed, Ali S.
    Kadi, Adnan A.
    ACTA CHROMATOGRAPHICA, 2025,
  • [5] A Rapid and Sensitive UPLC-MS/MS Method for Quantifying Capmatinib in Human Liver Microsomes: Evaluation of Metabolic Stability by In Silico and In Vitro Analysis
    Attwa, Mohamed W.
    Abdelhameed, Ali S.
    Alsibaee, Aishah M.
    Kadi, Adnan A.
    SEPARATIONS, 2023, 10 (04)
  • [6] Quantitative bioanalytical assay for the human epidermal growth factor receptor (HER) inhibitor dacomitinib in rat plasma by UPLC-MS/MS
    Qiu, Xiangjun
    Lin, Qianmeng
    Ning, Zongdi
    Qian, Xin
    Li, Pengbo
    Ye, Lei
    Xie, Saili
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2019, 166 : 66 - 70
  • [7] A validated UPLC-MS/MS assay of E7090, a novel selective inhibitor of fibroblast growth factor receptors, in human plasma and urine
    Asakawa, Yoshiki
    Sano, Takuya
    Hotta, Koichiro
    Miyajima, Yukiko
    Mano, Yuji
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2023, 225
  • [8] Ultra-fast UPLC-MS/MS - MS/MS approach for estimating X-376 in human liver microsomes: Evaluation of metabolic stability via in silico software and in vitro analysis
    Attwa, Mohamed W.
    Abdelhameed, Ali S.
    Kadi, Adnan A.
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2024, 128
  • [9] An LC-MS/MS Analytical Method for Quantifying Tepotinib in Human Liver Microsomes: Application to In Vitro and In Silico Metabolic Stability Estimation
    Attwa, Mohamed W.
    Mostafa, Gamal A. E.
    AlRabiah, Haitham
    Kadi, Adnan A.
    SEPARATIONS, 2023, 10 (06)
  • [10] LC-MS/MS method for the quantification of the anti-cancer agent infigratinib: Application for estimation of metabolic stability in human liver microsomes
    Mostafa, Gamal A. E.
    Kadi, Adnan A.
    AlMasoud, Najla
    Attwa, Mohamed W.
    Al-Shakliah, Nasser S.
    AlRabiah, Haitham
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2021, 1179